Etaze HT Cream is a topical formulation combining Hydroquinone (2% w/w), Mometasone (0.1% w/w), and Tretinoin (0.025% w/w) designed for the effective management of hyperpigmentation and inflammatory skin conditions. Hydroquinone acts as a potent skin-lightening agent by inhibiting melanin synthesis, thereby reducing dark spots, melasma, and other pigmentary disorders. Mometasone, a medium-potency corticosteroid, provides anti-inflammatory and anti-pruritic effects, helping to alleviate redness, swelling, and irritation associated with skin conditions. Tretinoin, a retinoid derivative, promotes epidermal cell turnover and enhances collagen production, improving skin texture and facilitating the fading of pigmentation. The synergistic combination in Etaze HT Cream targets both the underlying inflammation and pigmentation abnormalities, making it suitable for conditions like melasma, post-inflammatory hyperpigmentation, and other resistant pigmentary disorders. It should be used under medical supervision due to the presence of corticosteroids and retinoids, which may cause side effects such as skin thinning, irritation, or photosensitivity if misused. Patients are advised to apply a thin layer to the affected area once daily, preferably at night, and to use sunscreen during the day to prevent UV-induced pigmentation. Etaze HT Cream offers a comprehensive approach to managing complex pigmentary issues with enhanced efficacy.